Profile data is unavailable for this security.
About the company
Antengene Corporation Limited is a clinical-stage Asia-Pacific biopharmaceutical company focused on innovative oncology medicines. The Company is principally engaged in the discovery, development, manufacturing and commercialization of biotech products. The Company’s products include ATG-010 (selinexor), treating for relapsed/refractory multiple myeloma, relapsed/refractory diffuse large B-cell lymphoma and non-small cell lung cancer and ATG-008 (onatasertib), treating for hepatocellular carcinoma and non-small cell lung cancer. The Company mainly conducts its business in Asia-Pacific.
- Revenue in HKD (TTM)72.31m
- Net income in HKD-624.40m
- Incorporated2018
- Employees201.00
- LocationAntengene Corporation LtdUgland HousePO Box 309SHANGHAI KY1-1104ChinaCHN
- Websitehttps://www.antengene.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Clover Biopharmaceuticals Ltd | 42.17m | -148.84m | 382.63m | 387.00 | -- | -- | -- | 9.07 | -0.1192 | -0.1192 | 0.0338 | -0.6074 | 0.0116 | 0.0098 | 0.7449 | 108,977.30 | -4.08 | -- | -16.40 | -- | 61.75 | -- | -352.92 | -- | 0.5281 | -1.45 | -- | -- | -- | -- | 94.35 | -- | -- | -- |
Sirnaomics Ltd | 0.00 | -614.58m | 415.41m | 145.00 | -- | 1.32 | -- | -- | -8.08 | -8.08 | 0.00 | 3.58 | 0.00 | -- | -- | 0.00 | -70.91 | -- | -71.22 | -- | -- | -- | -- | -- | -- | -- | 0.6176 | -- | -- | -- | 10.88 | -- | -- | -- |
Antengene Corporation Ltd | 72.31m | -624.40m | 438.68m | 201.00 | -- | 0.3559 | -- | 6.07 | -1.01 | -1.01 | 0.1176 | 1.83 | 0.0358 | 0.9773 | 3.41 | 359,752.10 | -30.91 | -53.57 | -36.46 | -58.94 | 81.74 | -- | -863.51 | -1,987.01 | 6.43 | -- | 0.1491 | -- | -57.97 | -- | 3.38 | -- | 202.03 | -- |
Kintor Pharmaceutical Ltd | 0.00 | -1.14bn | 460.92m | 225.00 | -- | 0.9365 | -- | -- | -2.65 | -2.65 | 0.00 | 1.10 | 0.00 | 0.1448 | -- | 0.00 | -72.55 | -50.15 | -89.09 | -58.43 | -- | -27.62 | -- | -10,511.41 | 2.10 | -- | 0.3566 | -- | -- | -- | -11.15 | -- | -32.49 | -- |
HighTide Therapeutics Inc | 0.00 | -1.01bn | 571.40m | 66.00 | -- | 0.6951 | -- | -- | -2.13 | -2.13 | 0.00 | 1.60 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0229 | -- | -- | -- | -393.76 | -- | -- | -- |
Genor Biopharma Holdings Ltd | 0.00 | -724.51m | 632.44m | 104.00 | -- | 0.4851 | -- | -- | -1.43 | -1.43 | 0.00 | 2.54 | 0.00 | 0.00 | -- | 0.00 | -37.91 | -55.46 | -44.02 | -63.73 | -- | 66.56 | -- | -14,819.18 | 5.38 | -- | 0.006 | -- | -100.00 | -- | 7.65 | -- | -48.85 | -- |
JW (Cayman) Therapeutics Co Ltd | 186.78m | -825.11m | 747.12m | 398.00 | -- | 0.4103 | -- | 4.00 | -2.00 | -2.00 | 0.4539 | 4.39 | 0.0704 | 1.68 | 65.54 | 469,308.80 | -31.11 | -39.77 | -35.21 | -44.00 | 50.74 | -- | -441.74 | -1,316.81 | 3.86 | -47.82 | 0.1592 | -- | 19.32 | -- | 9.23 | -- | -19.87 | -- |
Brii Biosciences Ltd | 662.88k | -187.83m | 766.49m | 128.00 | -- | 0.2286 | -- | 1,156.30 | -0.2582 | -0.2582 | 0.0009 | 4.59 | 0.0002 | -- | -- | 5,178.78 | -5.60 | -- | -5.84 | -- | -- | -- | -29,881.69 | -- | -- | -- | 0.001 | -- | -98.80 | -- | 63.90 | -- | -- | -- |
Sunho Biologics Inc | -100.00bn | -100.00bn | 968.20m | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -155.25 | -- | -- | -- |
Data as of Jul 23 2024. Currency figures normalised to Antengene Corporation Ltd's reporting currency: Hong Kong Dollar HKD
6.41%Per cent of shares held by top holders
Holder | Shares | % Held |
---|---|---|
Fidelity Management & Research Co. LLCas of 08 Nov 2022 | 20.25m | 3.00% |
Zeal Asset Management Ltd.as of 31 Dec 2023 | 6.32m | 0.94% |
Fidelity Management & Research (Hong Kong) Ltd.as of 08 Nov 2022 | 5.04m | 0.75% |
Bosera Asset Management Co., Ltd.as of 31 Dec 2023 | 3.90m | 0.58% |
Fidelity Management & Research (Japan) Ltd.as of 08 Nov 2022 | 3.68m | 0.55% |
Norges Bank Investment Managementas of 31 Dec 2023 | 1.82m | 0.27% |
China Universal Asset Management Co., Ltd.as of 31 Dec 2023 | 1.51m | 0.22% |
Dimensional Fund Advisors LPas of 03 Jul 2024 | 677.50k | 0.10% |
Dimensional Fund Advisors Ltd.as of 31 May 2024 | 60.23k | 0.01% |
American Century Investment Management, Inc.as of 31 May 2024 | 12.50k | 0.00% |
More ▼
Data from 31 Dec 2023 - 17 Jul 2024Source: FactSet Research Systems Inc.